FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Diltiazem Hydrochloride
Status: Currently in Shortage
»Date first posted: 02/21/2018
»Therapeutic Categories: Cardiovascular

Expand all

Akorn Pharmaceuticals (Revised 07/30/2018)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10) Short supply, on allocation. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection (Premier) 25 mg / 5 mL, 10 mL, 10 vials (NDC 17478-0817-10) Short supply, on allocation. Will not produce further batches of this NDC#. Demand increase for the drug
Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 1 vial (NDC 17478-0817-25) Backordered. Batch release 8/3 will fill backorders. Will not produce further batches of this NDC#. Demand increase for the drug
Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 10 vials (NDC 17478-0817-26) Backordered. Will not produce further batches of this NDC#. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25) Backordered. Batch release on 8/3 will partially fill back order. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26) Backordered. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05) Short supply, on allocation. Batch release on 8/3 will partially fill back order. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection (Premier) 0.5 mg / mL, 30 gram, 10 vials (NDC 17478-0817-05) Short supply, on allocation. Batch release on 8/10 will fill back order. Will not produce further batches of this NDC#. Demand increase for the drug

Hospira, Inc. (Revised 12/06/2018)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03) Next Delivery: January 2019; Estimated Recovery: September 2019 Demand increase for the drug
25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01) Next Delivery and Estimated Recovery: 2019 Shortage per Manufacturer: Manufacturing Delay Other
50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02) Next Delivery and Estimated Recovery: 2019 Shortage per Manufacturer: Manufacturing Delay Other

West-Ward Pharmaceuticals (Reverified 09/10/2018)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
5 mg/mL, 5 mL vial (NDC 0641-6013-10) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured in the September - October 2018 timeframe. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 10 mL vial (NDC 0641-6014-10) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured in the September - October 2018 timeframe. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 30 mL vial (NDC 0641-6015-10) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured in the September - October 2018 timeframe. Product will be made available as it is released. Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English